Therapie der H. pylori-Infektion - Immer notwendig - Pro

Literatur

• 1 Axon A TR, Forman D. Helicobacter gastroduodenitis: A serious infectious disease.  BMJ. 1997;  314 1430-1431
• 2 Blaser M J. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease.  J Infect Dis. 1999;  179 1523-1530
• 3 Ebert M PA, Malfertheiner P. Review article: pathogenesis of sporadic and familial gastric cancer - implications for clinical management and cancer prevention.  Alivent Pharmacol Ther. 2002;  16 1059-1066
• 4 Ekström M, Held M, Hansson L -E, Engstrand L, Nyrén O. Helicobacter pylori in Gastric cancer established by CagA immunoblot as a Marker of past infection.  Gastroenterology. 2001;  121 784-791
• 5 El-Omar E M, Rabkin C S, Gammon M D, Voughan T L, Risch H A, Schoenberg J B, Stanford J L, Mayne S T, Goedert J, Blot W J, Fraumeni J F, Chow W. Increased risk of noncardiogastric cancer associated with proinflammatory cytokine polymorphismus.  Gastroenterology. 2003;  124 1193-1201
• 6 Hamada H, Haruma K, Mihara M. et al . High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.  Aliment Pharmacol Ther. 2000;  14 729-735
• 7 Konturek J W, Konturek S J, Stachura J, Domschke W. Helicobacter pylori - positive peptic ulcer patients do not adapt to aspirin.  APT. 1998;  12 857-864
• 8 Malfertheiner P. Helicobacter pylori - Von der Grundlage zur Therapie. Thieme 2000 3. Auflage
• 9 Malfertheiner P, Megraud F, O’Morain C, Hungin A PS, Jones R, Axon A, Grahom D Y, Tytgat G. & the European Helicobacter pylori Study group (EHPSG) . Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 Consensus Report.  Alivent Pharmacol Ther. 2002;  16 167-180
• 10 Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Lind T, Veldhuyzen Van Zanten S JO, Wrangstadh M. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme.  Alivent Pharmacol Ther. 2002;  16 1-13
• 11 Peek R M, Blaser M J, Mays D J. et al . Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle.  Cancer Res. 1999;  59 6124-6431
• 12 Raghunath A, Hungin A P, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review.  Br Med J. 2003;  326 737
• 13 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper R J. Helicobacter pylori Infection and the Development of Gastric Cancer.  NEJM. 2001;  345 784-789
• 14 Yamaoka Y, Kodama T, Kashima K, Graham D Y. Antibody against Helicbacter pylori CagA and VacA and the risk for gastric cancer.  J Clin Pahol. 1999;  52 215-218